- Hutchison China Meditech Limited (HCM) has expanded its global collaboration agreement with Innovent Biologics, Inc.
- The collaboration agreement is for evaluating the safety and efficacy of Innovent's sintilimab injection, Tyvyt® amalgamated with Chi-Med's surufatinib.
- The partnership will allow the two companies to jointly explore the potential application of Tyvyt® and surufatinib combination therapy in solid tumors with rising global demand.
- On 10th October 2019, at the time of writing, GMT 11:46 AM, HCM shares were trading at USD 282.00, down by 5.75 points or 2.00 per cent against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.